These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7540385)

  • 21. Alpha-blockers in hypertension: growing recognition as first line therapy.
    Khokhani RC
    J Assoc Physicians India; 1998; Suppl 1():7-10. PubMed ID: 11229107
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.
    Lepor H
    Prostate Suppl; 1990; 3():75-84. PubMed ID: 1689172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The medication minute: terazosin.
    Bartek JK; McNamee M
    Urol Nurs; 1995 Jun; 15(2):67-8. PubMed ID: 7541161
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of alpha 1-blockade in benign prostatic hyperplasia.
    Brawer MK
    J Clin Pharmacol; 1993 Sep; 33(9):891-5. PubMed ID: 7693769
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Stockamp K
    Urologe A; 1995 Jan; 34(1):3-8. PubMed ID: 7533449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha blocker prazosin for the treatment of benign prostatic hypertrophy (BPH).
    Punekar SV; Kelkar AR; Gavande PM; Rao NR; Date JA; Prem AR
    J Postgrad Med; 1995; 41(4):99-101. PubMed ID: 10707729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Terazosine in the treatment of benign prostatic hypertrophy].
    Caine M
    J Urol (Paris); 1993; 99(6):311-3. PubMed ID: 7516376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the best medical treatment for benign prostate hyperplasia?
    Evans MF; Frank J
    Can Fam Physician; 1997 Jun; 43():1073-4. PubMed ID: 9189295
    [No Abstract]   [Full Text] [Related]  

  • 29. [Alpha blockers in the treatment of benign hyperplasia of the prostate].
    Gómez Sancha F; Fernández Arjona M; Peinado Ibarra F; Fernández Borrell A; Mínguez Martínez R; Pereira Sanz I
    Rev Clin Esp; 1997 May; 197(5):358-62. PubMed ID: 9280971
    [No Abstract]   [Full Text] [Related]  

  • 30. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Alpha Blockers in Hypertension with Benign Prostatic Hyperplasia.
    Mathur RP; Nayak S; Sivaramakrishnan R; Jain V
    J Assoc Physicians India; 2014 Sep; 62(9 Suppl):40-4. PubMed ID: 26245042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Terazosin vs finasteride for BPH.
    Zacks M
    J Fam Pract; 1996 Dec; 43(6):533. PubMed ID: 8969692
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
    Belayneh M; Korownyk C
    Can Fam Physician; 2016 Sep; 62(9):e523. PubMed ID: 27629686
    [No Abstract]   [Full Text] [Related]  

  • 34. Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension.
    Pool JL; Nelson EB; Taylor AA; Mitchell JR
    Br J Clin Pract Suppl; 1987 Dec; 54():9-14. PubMed ID: 2905162
    [No Abstract]   [Full Text] [Related]  

  • 35. Measures of Proscar, Hytrin, and Cardura side effects.
    Frankel S
    Neurourol Urodyn; 1997; 16(1):63-6. PubMed ID: 9021791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FPIN's clinical inquiries. Medical treatment of benign prostatic hyperplasia.
    Rich KT; Safranek S
    Am Fam Physician; 2008 Mar; 77(5):665-6. PubMed ID: 18350766
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical efficacy and safety of terazosine (setegis) in patients with benign prostatic hyperplasia with concomitant cardiovascular diseases].
    Trapeznikova MF; Gurevich MA; Pozdniakov KV; Tazina SIa; Bychkova NV
    Urologiia; 2005; (2):50-3. PubMed ID: 15989029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic controversies: clinical treatment of benign prostatic hyperplasia.
    Geller J; Kirchenbaum A; Lepor H; Levine AC
    J Clin Endocrinol Metab; 1995 Mar; 80(3):745-7. PubMed ID: 7533770
    [No Abstract]   [Full Text] [Related]  

  • 40. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.